Image Credit: Epiminder
Australian-based Epiminder has been developing a continuous EEG monitoring (iCEM™) system intended to be uses in the management of drug-resistant epilepsy.
The system consists of an EEG recording and transmitting device implanted under the scalp which wirelessly sends the brain activity data through the skin to the Minder Wearable. The rechargeable Minder Wearable receives and stores EEG recordings and then transfers them to a smartphone-based Minder App, which uploads them to the Minder Cloud, from which they can be retrieved and reviewed by healthcare providers.
On October 30, 2026, Epiminder announced that FDA has cleared an expansion of the Minder implantable EEG monitoring system’s indication to include adolescents as young as 12 with drug-resistant epilepsy. The company says the submission included clinical safety, biocompatibility and device-performance evidence relevant to adolescent patients. The announcement extends the system’s previously adult patient population, although detailed adolescent study results were not released. The system is labeled in the United States for up to three years of use.